Estrogen nucleus derivatives for use in the inhibition of sex steroid activity
AssigneeEndorecherche, Inc.
InventorsFernand Labrie, Yves M erand
Life of this patent
Estimating the term…
Loading patent…
AssigneeEndorecherche, Inc.
InventorsFernand Labrie, Yves M erand
Estimating the term…
Novel compounds for the inhibition of sex steroid activity for the treatment of both androgen-related and estrogen-related diseases include for example 15- and 16-halo substituted compounds such as: ##STR1## The compounds are characterized by an estrogenic nucleus substituted with a substituent of the formula --R.sup.1 [B--R.sup.2 --].sub.x L--G wherein at least one of n and G is a polar moiety distanced from a ring carbon of the estrogenic nucleus by at least three intervening atoms: x is an integer from 0--6; R.sup.1 and R.sup.2 are independently either absent or selected from the group consisting of straight- or branched-chain alkylene, straight- or branched-chain alkynylene, straight- or branched-chain alkenylene, phenylene, and fluoro-substituted analogs of the foregoing; and B is either absent or selected from the group consisting of --O-- --Se--, --SO--, --SO.sub.2 --, --NR.sup.3 --, --SiR.sup.3.sub.2, --CR.sup.3 OR.sup.3 --, NR.sup.3 CO--, NR.sup.3 CS--, --CONR.sup.3 --, CSNR.sup.3 --, --COO--, --COS--, --SCO--, --CSS--, --SCS--, --OCO-- and phenylene (R.sup.3 being hydrogen or lower alkyl).
A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of a sex steroid activity inhibitor having, as part of its molecular structure, a substituted or unsubstituted estrogenic nucleus of structure I ##STR58## wherein the dotted lines represent optional pi bonds and wherein said compound includes as another part of its molecular structure a side chain substituted onto a ring carbon of said structure I represented by the formula --R.sup.1 [--B--R.sup.2 --].sub.x L--G wherein at least one of said side chains is substituted at carbon 16, wherein:
A sex steroid activity inhibiting compound having, as part of its molecular structure, a substituted or unsubstituted estrogenic nucleus of structure I:
A method for inhibiting sex steroid activity comprising administering to a human or other warm-blooded animal in need of such treatment, with or without additional diluent or carrier, a pharmaceutically effective amount of a compound selected from the group consisting of ##STR60## wherein R.sup.3 and R.sup.17 are independently selected from the group consisting of H-- and C.sub.6 H.sub.5 C(O).
A method for treating an estrogen-related disease comprising administering to a patient afflicted with said disease in need of such treatment, with or without additional diluent or carrier, a pharmaceutically effective amount of a compound selected from the group consisting of ##STR61## wherein R.sup.3 and R.sup.17 are independently selected from the group consisting of H-- and C.sub.6 H.sub.5 C(O).
A method for treating an androgen-related disease comprising administering to a patient afflicted with said disease in need of such treatment, with or without additional diluent or carrier, a pharmaceutically effective amount of a compound selected from the group consisting of ##STR62## wherein R.sup.3 and R.sup.17 are independently selected from the group consisting of H-- and C.sub.6 H.sub.5 C(O).
A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of a sex steroid activity inhibitor having, as part of its molecular structure, a substituted or unsubstituted nucleus selected from the group consisting of:
A sex steroid inhibiting compound having, as part of its molecular structure, a substituted or unsubstituted nucleus selected from the group consisting of:
A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of at least one sex steroid inhibitor selected from the group consisting of:
A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of at least one sex steroid inhibitor selected from the group consisting of:
A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of at least one sex steroid inhibitor selected from the group consisting of:
A sex steroid activity inhibiting compound selected from the group consisting of:
A sex steroid activity inhibiting compound selected from the group consisting of:
A sex steroid activity inhibiting compound selected from the group consisting of:
Dependencies are inferred from the claim text.